{
    "clinical_study": {
        "@rank": "16672", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This multicenter, observational study will evaluate the use and efficacy of\n      RoActemra/Actemra (tocilizumab) in routine clinical practice in patients with moderate to\n      severe rheumatoid arthritis. Eligible patients initiated on RoActemra/Actemra treatment in\n      accordance with the local label will be followed for 6 months."
        }, 
        "brief_title": "A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) Treatment in Patients With Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Moderate to severe rheumatoid arthritis according to the revised (1987) ACR criteria\n\n          -  Patients in whom the treating physician has made the decision to commence\n             RoActemra/Actemra treatment (in accordance with the local label); this can include\n             patients who have received RoActemra/Actemra treatment within 8 weeks prior to the\n             enrolment visit\n\n        Exclusion Criteria:\n\n          -  Patients who have received RoActemra/Actemra more than 8 weeks prior to the enrolment\n             visit\n\n          -  Patients who have previously received RoActemra/Actemra in a clinical trial or for\n             compassionate use\n\n          -  Patients who have received treatment with any investigational agent within 4 weeks\n             (or 5 half-lives of the investigational agent, whichever is longer) before starting\n             treatment with RoActemra/Actemra\n\n          -  Patients with a history of autoimmune disease or any joint inflammatory disease other\n             than rheumatoid arthritis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with moderate to severe rheumatoid arthritis initiating treatment with\n        RoActemra/Actemra in accordance with the local label"
            }
        }, 
        "enrollment": {
            "#text": "210", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01952509", 
            "org_study_id": "ML28747"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Santo Domingo", 
                        "country": "Dominican Republic", 
                        "zip": "10208"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ciudad de Guatemala", 
                        "country": "Guatemala"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Dominican Republic", 
                "Guatemala"
            ]
        }, 
        "number_of_groups": "1", 
        "official_title": "Multinational, Multicenter, Non Interventional Study, in Patients With Rheumatoid Arthritis (RA) Treated With Tocilizumab.", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28747 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Guatemala: Ministerio de Salud de Guatemala (Guatemala MoH)"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of patients on RoActemra/Actemra at 6 months after treatment initiation", 
            "safety_issue": "No", 
            "time_frame": "approximately 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01952509"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Rates of dose modifications/interruptions", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Clinical/demographic patient characteristics at initiation of RoActemra/Actemra treatment", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Proportion of patients on RoActemra/Actemra monotherapy at study entry and at Month 6", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Efficacy: Response according to total joint count evaluation by DAS28/EULAR/SDAI/CDAI/ACR", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Health Assessment Questionnaire Disability Index", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Visual Analogue Scale - Fatigue", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Visual Analogue Scale - severity of pain", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Visual Analogue Scale - morning stiffness", 
                "safety_issue": "No", 
                "time_frame": "aproximately 2 years"
            }, 
            {
                "measure": "Patient Global Assessment of disease activity", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}